The TuBerculosis Vaccine Initiative (TBVI) Governance Board would like to announce a vacancy for the Executive Director of the organization. The Board has launched the search for a new Director with immediate effect and a closing date of October 19, 2023.
The development of novel TB vaccines has never been more relevant and urgent, and this opening is a unique opportunity to lead an organization that is at the forefront of TB vaccine research, innovation and development. Interested individuals are invited to express their intent to info@tbvi.eu. The Terms of Reference for the post are available upon request.
TBVI is a research, innovation and development partnership that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable globally. As a non-profit foundation, TBVI creates an enabling environment for TB vaccine research, innovation and product development. TBVI supports its partners to develop and move the most promising TB vaccine and biomarker candidates through the product development pipeline. To continue to innovate and diversify the pipeline and TB vaccine platforms, TBVI supports collaborative research and innovation by its partners. TBVI adds value through providing services of technical advice for product and clinical development; project identification, development and management; and resource mobilization. TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to strengthen global and European cooperation and coordination and identifies gaps to move the field forward. TBVI is now entering a phase to become closer to key European institutions as it continues to work to strengthen European leadership and scientific excellence in TB vaccine research, innovation and development. To that end, TBVI is seeking to establish a stronger presence in Brussels and forge closer alliances with like-minded product development partnerships across TB and across vaccines. For more information, check the website: www.tbvi.eu